Evidence map›Paper›PMID 24369304›Full record

ArticleLeukemia2014

Bone marrow monocyte-/macrophage-derived activin A mediates the osteoclastogenic effect of IL-3 in multiple myeloma.

R Silbermann, M Bolzoni, P Storti, D Guasco, S Bonomini, D Zhou, J Wu, J L Anderson, J J Windle, F Aversa and 2 more

Open access · hybridAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 56 citations in OpenAlex.

  1. Article
  2. Frontiers in pharmacology · 2025
    Review
  3. Review
  4. Aster saponin AJournal of veterinary science · 2022
    Article
  5. Carnosol inhibits osteoclastogenesisMolecular medicine reports · 2022
    Article
  6. Pathogenesis and Treatment of Myeloma-Related Bone Disease.International journal of molecular sciences · 2022
    Review
  7. Review
  8. Rosavin suppresses osteoclastogenesisAnnals of translational medicine · 2021
    Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Multiple Myeloma and Bone: The Fatal Interaction.Cold Spring Harbor perspectives in medicine · 2018
    Review
  17. Review
  18. Role of Galectins in Multiple Myeloma.International journal of molecular sciences · 2017
    Review
  19. Article
  20. Haematologica · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

R SilbermannDepartment of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
M BolzoniDepartment of Hematology, University of Parma, Parma, Italy.
P StortiDepartment of Hematology, University of Parma, Parma, Italy.
D GuascoDepartment of Hematology, University of Parma, Parma, Italy.
S BonominiDepartment of Hematology, University of Parma, Parma, Italy.
D ZhouDepartment of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
J WuDepartment of Biostatistics, Indiana University School of Medicine, Indianapolis, IN, USA.
J L AndersonDepartment of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
J J WindleDepartment of Human Genetics, Virginia Commonwealth University, Richmond, VA, USA.
F AversaDepartment of Hematology, University of Parma, Parma, Italy.
G David Roodman1] Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA [2] Richard L. Roudebush Veterans Administration Medical Center, Indianapolis, IN, USA.
N GiulianiDepartment of Hematology, University of Parma, Parma, Italy.
University of Parma · ITIndiana University – Purdue University Indianapolis · USIndiana University School of MedicineVirginia Commonwealth University · US

Funding

Quality Assurance and Quality Control Project Management: Improving Submissions and Study Conduct in the Human Subjects Research Prior Approval ProcessUL1TR002529 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI MOE, SHARON M, WIEHE, SARAH ELIZABETH · 2018 to 2022
$27.2M
Indiana Clinical and Translational Sciences InstituteUL1TR001108 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI DENNE, SCOTT C., SHEKHAR, ANANTHA · 2013 to 2017
$23.3M
GFI-1 and Osteoblast Suppression in Multiple MyelomaR01AR059679 · NIAMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GALSON, DEBORAH LYNN, ROODMAN, GARSON DAVID · 2010 to 2014
$1.4M
NCATS NIH HHS UL1 TR001108NIAMS NIH HHS R01 AR059679
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ActivinsAnimalsBone DiseasesHumansInterleukin-3MacrophagesMiceMice, Inbred C57BLMonocytesMultiple MyelomaOsteoclastsOsteogenesisRANK Ligandactivin AActivinsInterleukin-3RANK Ligand

Identifiers

PMID24369304
PMCPMC3981881
OpenAlexW2005550178

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.